Market Movers (8-K)
OQB
Adia Med, Inc. has fully repaid and discharged its $1,000,000 unsecured revolving line of credit provided by its CEO, Larry Powalisz.
OQB
Adia Nutrition has initiated a legal action seeking to quiet title on over 29 million shares of its common stock, alleging they were improperly issued.
Worse than expected
OQB
Adia Nutrition, Inc. has entered into an engagement letter with Lucosky Brookman LLP to provide legal counsel for its planned uplisting to the NASDAQ Capital Market and a contemplated bridge financing transaction.
Capital raise
OQB
Adia Nutrition, Inc. has officially changed its corporate name to Adia Med, Inc., with the change effective June 2, 2026, and FINRA approval received on July 10, 2026.
Quarterly Earnings (10-Q)
OQB
ADIA Nutrition, Inc. filed its Q2 2026 10-Q, showing increased revenue but also a net loss and substantial doubt regarding its ability to continue as a going concern.
Capital raise
Worse than expected
Annual Reports (10-K)
OQB
ADIA Nutrition, Inc. reported a significant increase in revenue for fiscal year 2025, driven by its medical procedures and biologics segments, despite continuing net losses and substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected